OSR Holdings, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a OSRH research report →
Price Chart
About the company
OSR Holdings, Inc. operates as a Special Purpose Acquisition Company (SPAC) – essentially a blank check entity. Its primary objective is to execute a substantial business combination, which may take the form of a merger, a capital stock exchange, an asset acquisition, a stock purchase, a reorganization, or other comparable strategic transaction with one or more established businesses.
- CEO
- Kuk Hyoun Hwang
- IPO
- 2023
- Employees
- 22
- HQ
- Bellevue, WA, US
Get TickerSpark's AI analysis on OSRH
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $4.09M
- P/E
- -0.04
- PEG
- 0.00
- P/S
- 2.40
- P/B
- 0.00
- EV/EBITDA
- -0.37
- Div Yield
- 0.00%
- Gross Margin
- -117.91%
- Op Margin
- -946.74%
- Net Margin
- -874.67%
- ROE
- -14.01%
- ROIC
- -9.49%
Latest fiscal year · YoY change
- Revenue
- $2.91M-17.7%
- Gross Profit
- $592.90K-26.9%
- Op Income
- $-18,336,004
- Net Income
- $-18,010,899-74.4%
- EPS
- $-4.02-644.4%
- OCF Growth
- -97.8%
- FCF Growth
- -105.9%
- 52W High
- $0.91
- 52W Low
- $0.07
- 50D MA
- $0.37
- 200D MA
- $0.51
- Beta
- 0.57
- RSI (14)
- 46
- Avg Volume
- 10.07M
No earnings-call transcripts are available for OSRH yet.
- Free Float
- 44.2%
- Shares Outstanding
- 35.12M
- Float Shares
- 14.65M
of shares held by institutions
11 13F filers
Buy/sell ratio 0.56. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Citadel Advisors LLC | 127.81K | ▲ 127.81K |
| Vanguard Group Inc | 54.40K | 0 |
| Two Sigma Securities, LLC | 46.54K | ▲ 46.54K |
| Xtx Topco Ltd | 32.38K | ▼ 28.37K |
| Susquehanna International Group, Llp | 18.28K | ▲ 18.28K |
| Northern Trust Corp | 10.91K | ▲ 10.91K |
| Tower Research Capital LLC (Trc) | 6.59K | ▲ 2.45K |
| Skyview Investment Advisors, LLC | 3.00K | ▲ 3.00K |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 29, 26 | Hwang Kuk Hyoun | other | 1,173,697 |
| Oct 29, 26 | Kim Yeiseok | other | 293,422 |
| Oct 29, 26 | Bang Gihyoun | other | 440,137 |
| Oct 29, 26 | Cho Joong Myung | other | 120,000 |
| Oct 29, 26 | Barberis Alcide | other | 120,000 |
| Oct 29, 26 | Mah Seng Chin | other | 120,000 |
| Feb 14, 25 | Mah Seng Chin | other | 0 |
| Mar 26, 26 | Kim Yeiseok | other | 0 |
| Sep 17, 25 | Fierz Reto Kaspar | other | 0 |
| Feb 14, 25 | Cho Joong Myung | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our OSRH coverage
Recent articles, reports, and earnings notes.
No research on OSRH yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate OSRH report →Reviewing Madrigal Pharmaceuticals (NASDAQ:MDGL) & OSR (NASDAQ:OSRH)
defenseworld.net · Nov 5
Emerging Growth Research Issues Company-Sponsored Research Flash Report on OSR Health, Inc.
accessnewswire.com · Aug 27
OSR Health: Preparing Our Appeal, Advancing Our Catalysts, Continuing Our Mission
accessnewswire.com · Aug 21
OSR Health Receives Nasdaq Staff Delisting Determination and Intends to Request Hearings Panel Appeal
accessnewswire.com · Aug 19
OSR Health Sees Global Shareholder Momentum at Critical Inflection Point
accessnewswire.com · Aug 19
OSR Health CEO Reaffirms Confidence and Highlights Subsidiary Business Development
accessnewswire.com · Aug 11
OSR Health Issues Clarification Regarding Prior Nasdaq Communication and Shareholder Loyalty CVR Program
accessnewswire.com · Aug 7
Vaximm AG, an OSR Company, Announces Forthcoming Publication of Cross-Indication Clinical Data for VXM01, Its VEGFR-2-Targeted Cancer Vaccine Platform
accessnewswire.com · Aug 3
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.